Galapagos NV (NASDAQ:GLPG) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 805,865 shares, a growth of 39.5% from the May 31st total of 577,527 shares. Based on an average daily trading volume, of 171,148 shares, the short-interest ratio is presently 4.7 days.

A number of institutional investors have recently added to or reduced their stakes in GLPG. Marshall Wace LLP increased its position in Galapagos NV by 21.7% in the fourth quarter. Marshall Wace LLP now owns 7,340 shares of the biotechnology company’s stock worth $471,000 after buying an additional 1,311 shares during the period. Renaissance Technologies LLC increased its position in Galapagos NV by 46.6% in the fourth quarter. Renaissance Technologies LLC now owns 205,500 shares of the biotechnology company’s stock worth $13,191,000 after buying an additional 65,300 shares during the period. Castleark Management LLC increased its position in Galapagos NV by 136.9% in the fourth quarter. Castleark Management LLC now owns 7,890 shares of the biotechnology company’s stock worth $506,000 after buying an additional 4,560 shares during the period. Macquarie Group Ltd. bought a new position in Galapagos NV during the fourth quarter worth about $749,000. Finally, Bank of Montreal Can increased its position in Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock worth $168,000 after buying an additional 1,922 shares during the period. Institutional investors and hedge funds own 19.94% of the company’s stock.

Galapagos NV (NASDAQ GLPG) opened at 76.25 on Friday. Galapagos NV has a 12 month low of $50.81 and a 12 month high of $94.88.

GLPG has been the subject of several recent research reports. Zacks Investment Research raised Galapagos NV from a “hold” rating to a “buy” rating and set a $82.00 price objective for the company in a research report on Tuesday, March 7th. Janney Montgomery Scott cut Galapagos NV from a “buy” rating to a “sell” rating in a research report on Monday, April 24th. Stifel Nicolaus upped their price objective on Galapagos NV from $65.00 to $83.00 and gave the stock a “hold” rating in a research report on Monday, May 1st. TheStreet raised Galapagos NV from a “d+” rating to a “c” rating in a research report on Wednesday, May 17th. Finally, Instinet reaffirmed a “buy” rating and set a $108.00 price objective (down from $121.00) on shares of Galapagos NV in a research report on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Galapagos NV presently has a consensus rating of “Buy” and a consensus price target of $94.00.

ILLEGAL ACTIVITY WARNING: “Galapagos NV (GLPG) Short Interest Up 39.5% in June” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/30/galapagos-nv-glpg-short-interest-up-39-5-in-june.html.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.